Abstract

The genome represents a design for creating the body, with each one being different. In cancer genomic medicine, many genes are simultaneously examined using mainly cancer tissues the oncogene panel test , and gene mutations are revealed. Cancer treatments are then initiated according to each individual's constitution and medical condition based on gene mutations. A system for cancer genome medical treatment is currently being developed. In the treatment of several cancer types, the "oncogene test with an oncogene companion diagnosis" is already being performed as a standard test using cancer tissue to detect one or several gene mutations. Precision Medicine discovering unique therapies that treat an individual's cancer based on the specific abnormalities, i.e. germline or somatic mutations of their tumors. In this paper, we will explain the biological role of C MYC and emphasize the importance of C MYC as a target factor in cancer precision medicine. The functional activated C MYC for cell proliferation and tumorigenesis is potential candidate as anti oncogenic molecule. Takuma Hayashi | Ikuo Konishi "Cancer Precision Medicine: Physiological Function of C-MYC as Targeted Molecule" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-5 , August 2019, URL: https://www.ijtsrd.com/papers/ijtsrd28030.pdfPaper URL: https://www.ijtsrd.com/medicine/other/28030/cancer-precision-medicine-physiological-function-of-c-myc-as-targeted-molecule/takuma-hayashi

Authors and Affiliations